Generation of a homology model of the human histamine H₃  receptor for ligand docking and pharmacophore-based screening by Schlegel, Birgit et al.
Generation of a homology model of the human histamine H3
receptor for ligand docking and pharmacophore-based screening
Birgit Schlegel Æ Christian Laggner Æ Rene Meier Æ
Thierry Langer Æ David Schnell Æ Roland Seifert Æ
Holger Stark Æ Hans-Dieter Ho¨ltje Æ Wolfgang Sippl
Received: 20 November 2006 / Accepted: 29 June 2007
 Springer Science+Business Media B.V. 2007
Abstract The human histamine H3 receptor (hH3R) is a
G-protein coupled receptor (GPCR), which modulates the
release of various neurotransmitters in the central and
peripheral nervous system and therefore is a potential
target in the therapy of numerous diseases. Although
ligands addressing this receptor are already known, the
discovery of alternative lead structures represents an
important goal in drug design. The goal of this work was
to study the hH3R and its antagonists by means of
molecular modelling tools. For this purpose, a strategy
was pursued in which a homology model of the hH3R
based on the crystal structure of bovine rhodopsin was
generated and refined by molecular dynamics simulations
in a dipalmitoylphosphatidylcholine (DPPC)/water mem-
brane mimic before the resulting binding pocket was used
for high-throughput docking using the program GOLD.
Alternatively, a pharmacophore-based procedure was car-
ried out where the alleged bioactive conformations of three
different potent hH3R antagonists were used as templates
for the generation of pharmacophore models. A pharma-
cophore-based screening was then carried out using the
program Catalyst. Based upon a database of 418 validated
hH3R antagonists both strategies could be validated in re-
spect of their performance. Seven hits obtained during this
screening procedure were commercially purchased, and
experimentally tested in a [3H]Na-methylhistamine binding
assay. The compounds tested showed affinities at hH3R
with Ki values ranging from 0.079 to 6.3 lM.
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Introduction
The histamine H3 receptor was discovered in 1983 by
Arrang and co-workers [1] and has been the focus of
intense research for over more than 20 years since then.
Recently, several review articles have been published on
the histamine H3 receptor, [2] H3R isoforms, [3, 4] on
H3R antagonists [5, 6] and agonists, [7] which summarise
the current knowledge on this receptor. Briefly, the hH3R
is a GPCR protein expressed presynaptically in several
regions of the central and peripheral nervous system
where it functions either as an autoreceptor regulating the
release of histamine from histaminergic neurons or as an
heteroreceptor regulating the release of several other
B. Schlegel  H.-D. Ho¨ltje
Institute of Pharmaceutical Chemistry,
Heinrich-Heine-Universita¨t Du¨sseldorf,
Universita¨tsstr. 1, 40197 Dusseldorf, Germany
C. Laggner  T. Langer
Institute of Pharmaceutical Chemistry,
Leopold-Franzens-Universita¨t Innsbruck,
Innrain 52, Innsbruck 6020, Austria
R. Meier  W. Sippl (&)
Department of Pharmaceutical Chemistry,
Martin-Luther Universita¨t Halle-Wittenberg,
Wolfgang-Langenbeckstr. 4, 06120 Halle/Saale, Germany
e-mail: wolfgang.sippl@pharmazie.uni-halle.de
D. Schnell  R. Seifert
Department of Pharmacology and Toxicology,
Institute of Pharmacy, University of Regensburg,
93040 Regensburg, Germany
H. Stark
Institute of Pharmaceutical Chemistry, Biozentrum,
ZAFES/CMP, Johann Wolfgang Goethe-Universita¨t,
60438 Frankfurt, Germany
123
J Comput Aided Mol Des
DOI 10.1007/s10822-007-9127-x
neurotransmitters. Due to this regulatory function it is
expected that the hH3R could be exploited as a potential
target for several therapeutic applications including
obesity, cognitive disorders and insomnia.
In recent years, the number of hH3R ligands has rapidly
increased due to the combined effort of university research
groups and pharmaceutical companies. In order to find new
hH3R ligands, initially, derivatives of the intrinsic ligand
histamine were generated leading to the class of imidazole-
containing compounds [for a review see 6, 7]. Due to
several potential drawbacks of the imidazole-moiety
(interaction with P450 enzymes, substrate of the inacti-
vating enzyme, histamine Ns-methyl transferase, and low
CNS penetration1) great effort was put into the replacement
of this moiety, resulting in the nowadays heterogeneous
class of non-imidazole ligands containing mostly piperi-
dine, pyrrolidine or structurally related groups [10, for a
review see 5, 7]. In most cases new compounds were de-
signed from scratch or by variation of hits found during
in vitro screening of large compound libraries. Examples
of hH3R antagonists are given in Fig. 1.
Recently, the successful application of in silico screen-
ing tools such as ligand docking or pharmacophore based
screening for retrieving GPCR antagonists was shown,
[11–15]. Several in silico studies have already been carried
out on the hH3R focusing however mainly on the place-
ment of ligands in the binding pocket and on the derivation
of a putative binding site for reasoning the design of new
compounds rather than on an automatic screening for new
compounds. In 2000 De Esch et al. [16, 17] published a
study on imidazole-containing hH3R ligands and proposed
a pharmacophore model consisting of a common anchor
site for the imidazole moiety which was expected to
interact with E5.46 in helix 5, and two lipophilic pockets.
At the same time branched compounds published by
Schering in the patent application WO00/53596 confirmed
the existence of two lipophilic pockets.
The first H3R homology model based on the crystal
structure of bovine rhodopsin was published in 2001 by
Sippl et al. [18] with the aim of explaining the striking
species differences observed for some antagonists on the
rat versus the human hH3R [19, 20]. In the complexes
studied, the imidazole moiety of antagonists was—in
analogy with the imidazole moiety of histamine—assumed
to interact with E5.462. In 2002, Uveges and co-workers
studied the natural agonist histamine in an hH3R homology
model [22]. Histamine was manually placed such as to
contact E5.46 with its imidazole moiety and D3.32 with its
primary amine functionality. In order to simultaneously
establish an interaction of histamine with D3.32 and E5.46,
manual adjustments of helix 5 were required. Interestingly,
Uveges further reported that the mutation E5.46A had only
minor effects on the binding of the protean ligand
[125I]iodoproxyfan, which was later supported also by
Jacobsen et al. who analysed binding of iodoproxyfan to an
E5.46Q hH3R mutant [23]. In the same study of Jacobsen
and coworkers it was concluded that a common feature of
antagonists, which were most affected by the E5.46Q
mutation, i.e. iodophenpropit, clobenpropit and NNC-
0038–1035, was the presence of structural groups in their
side-chain, which could make interactions with the car-
boxylic acid in E5.46. Implicitly, it was thus suggested that
the imidazole moiety of these antagonists was in contact
with D3.32.
In 2003, Yao and co-workers [24] further attempted to
explain species differences observed for the binding of
antagonists such as A-304121, and showed that by carrying
out the point mutations A3.37T and V3.40A in the rat H3R,
the binding profile of the human H3R was restored. Dif-
ferent to the model of Sippl et al. which suggested an
indirect influence of amino-acids varying between species,
in the model of Yao antagonists made a direct contact to
those residues, resulting in a ligand placement extending
from D3.32 orthogonal to the membrane plane down to
residue D2.50 [25, 26]. In 2005, a model of the rat H3R was
published by Lorenzi et al. which was used to guide the
successful design of further imidazole-containing H3R
compounds [27]. Antagonists were placed into the
homology model starting from the hypothesis that their
imidazole ring interacted with E5.46. Very recently, a
further modelling study on the hH3R was published by Axe
et al. [28] in which complexes of the hH3R with bi-cationic
antagonists were studied by means of MD simulation in a
continuum dielectric membrane model. The compounds
were manually docked such as to contact both D3.32 and
E5.46. The question of how mono-cationic compounds
would be oriented in the binding site had not been
addressed.
In the present work, two well established tools for in
silico screening, namely molecular docking into a rho-
dopsin-based homology model and a pharmacophore
based search, were carried out for the target hH3R. The
hH3R ligand dataset is extremely challenging in this re-
spect as the ligands are in most cases highly flexible and
different inverse agonist classes interact with different
sets of receptor site points. Furthermore, the low number
of mutational studies published for the hH3R merely
indicated the approximate position of the ligands in the
hH3R model rather than giving a detailed view on the
amino acid side chains involved in ligand binding. Still,
1 low CNS penetration can also be an advantage in situations where a
peripheral application of hH3 ligands is pursued, such as the design of
nasal decongestants by Schering or cytoprotective agents. [8, 9]
2 numbering scheme according to Ballesteros et al. [21]: the most
conserved residue in each transmembrane segment is assigned posi-
tion 50. The first number refers to the helical segment.
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the existence of a large dataset of experimentally tested
hH3R inverse agonists aided the generation and the sub-
sequent validation of hH3R homology- and ligand-based
pharmacophore-models.
In order to obtain a binding site suitable for subsequent
ligand docking, complexes of the hH3R with antagonists
were simulated in a DPPC/water environment. The pro-
tonated headgroup of the ligands was thereby oriented such
as to contact D3.32. The resulting receptor binding site and
the pharmacophore models were then applied in a virtual
screening experiment using a validated data set of known
hH3R ligands. A significant portion of validated actives
could be retrieved by applying either method indicating
that both the generated receptor binding site and the
pharmacophore models are suitable for virtual screening. In
order to test the predictive value of the generated model,
seven hits obtained during the screening procedures were
purchase from the Maybridge Database (MDB) and tested
for their affinity in a [3H]Na-methylhistamine binding
experiment.
Fig. 1 Structures of hH3R
antagonists mentioned in the
text
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Materials and methods
Generation of homology models of the hH3R and hH3R
ligand complexes
A model of the human histamine H3 receptor was gener-
ated based on the crystal structure 1HZX of bovine rho-
dopsin [29]. The initial sequence-structure alignment was
based on multiple sequence alignments, the prediction of
secondary structure, transmembrane helices and highly
conserved residues identified by Ballesteros et al. [21] and
resulted to be identical to the alignment shown by Mor and
coworkers [27]. After truncating the 3rd intracellular loop
to a comparable length as present in the template structure
bovine rhodopsin by excising the stretch A240-Q346 from
the hH3R sequence, amino acid side chain conformations
were added using program SCWRL3.0 [30]. One internal
water molecule was included in the hH3R receptor model,
which was located in proximity to D2.50 and linked helices
2, 3 and 7 at a comparable position as water molecule 1b in
the structure of bovine rhodopsin [26].
For generating a FUB836/hH3R complex, FUB836 was
flexibly docked into a set of alternative hH3R binding
sites generated by assuming alternative rotamers for
several amino acid residues lining the binding pocket (see
Table 1) using the program GOLD version 2.3 [31].
During this docking procedure, a distance constraint was
applied between the piperidyl-nitrogen of FUB836 and
D3.32. The resulting complexes were ranked according to
the obtained GoldScores and the potential energy of the
FUB836 conformation within these complexes was cal-
culated. The highest ranked FUB836/hH3R complex was
used as a starting conformation for MD simulation. The
orientation of FUB836 in the hH3R binding pocket is
shown in Fig. 2.
Calculation of pKa-shifts in the hH3R binding pocket
Calculation of pKa-shifts was carried out using the program
UHBD [32] with default settings. Calculation of pKa-shifts
were carried out for the uncomplexed hH3R model com-
prising one internal water molecule, and for a complex of
VUF5300/hH3R, in which the piperidyl-moiety of
VUF5300 was interacting with D3.32 and the imidazole
group was interacting with E5.46.
Molecular dynamics simulations of hH3R models
All MD simulations were carried out using the program
GROMACS and the ffG43a1 force filed [33, 34]. For
testing the influence of alternative rotamer conformations
for specific residues on the resulting binding pocket
geometry, MD simulations of uncomplexed hH3R models
in a CCl4/water membrane mimic were carried out. A
CCl4/solvent box of the dimensions 8.56 · 6.45 · 9.01 nm
was generated and the hH3R models were simulated
without applying any constraints on the model. The gen-
eration and equilibration of the CCl4/solvent box, the
insertion of the receptor into this box and the subsequent
simulation of the receptor were carried out in analogy to
the simulation of bovine rhodospin in a CCl4/solvent box
(see [35] for details).
For the simulation of the FUB836/hH3R ligand receptor
complex, a DPPC/water box was used comprising 92 DPPC
molecules, 7085 solvent molecules, 11 sodium and 27
chlorine atoms. The insertion of the ligand receptor complex
into this membrane mimic, details on equilibration and
simulations are described in reference [35] for the analogue
simulation of bovine rhodopsin. During the simulation of
the FUB836/hH3R model the following interhelical hydro-
gen bond contacts were restrained by applying the following
Table 1 Residues used in the approach of inverse docking
TM Residues
1 –
2 V2.53, C2.57, I2.58, Y2.61(3)
3 W3.28(3), L3.29, D3.32(3), Y3.33(3), L3.35, C3.36(2),
T3.37(3)
4 Y4.57(2)
5 L5.39, A5.42, S5.43, E5.46(3), F5.47
6 W6.48, Y6.51, T6.52(3), M6.55, I6,56
7 F7.39, W7.40, L7.42, W7.43(5), S7.46
E2 A5.30
Residues lining the hH3R binding pocket, for which various rotamers
had been considered (number of alternative rotamers given in
parentheses) or which had been included as additional constraints for
docking FUB836. Amino acids in contact with the ligands are made in
boldface
Fig. 2 Orientation of FUB836 in the hH3R binding pocket
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distance constraints: N1.50:ND2-S7.46:O, N2.45:ND2-
N3.42:OD1, N2.45:OD1-W4.50:HE1, L7.55:O-R7.61:NH1,
D2.50:OD2-H2O:OW, S3.39:OG-H2O:HW2, N7.49:OD1-
H2O:HW1 and Y4.57:HH-E5.46:OE2.
Ligand docking into the hH3R binding site
Docking was carried out using a inhouse dataset of 418
experimentally tested hH3R antagonists with a range of pKi
from 5.29 to 10.04. The structural diversity/similarity of
the 418 hH3R ligands was analyzed by carrying out a
cluster analyis in MOE2006.08 (Chemical Computing
Group, Montreal, Canada) using MACCS and graph-3-
point-pharmacophore fingerprints. Considering a conser-
vative Tanimoto cutoff of 0.8, 198 (MACCS) and 275
(graph-3-point-pharmacophore) individual clusters were
obtained, respectively. Histograms showing the individual
cluster populations are given in Fig. 3. Due to the fact that
the 418 ligand data set represents the result from a
medicinal chemistry guided optimisation strategy, indi-
vidual clusters show higher population including structur-
ally related analogs.
Ligand docking was carried out using the program
GOLD version 2.3 [31] and default parameters except
when otherwise indicated. For ligand docking, all com-
pounds were treated as being in their natural protonation
state under physiological conditions and all imidazole
groups were considered in their protonated form. During
the approach of inverse docking of FUB836 into various
hH3R binding pockets and for the validation experiments,
a ‘‘2-times accelerated’’ genetic algorithm was used and a
distance constraint was set between D3.32 and the pro-
tonated head group in order to guarantee the establish-
ment of this ionic interaction. When screening against the
unfocused library, the correction term 1=
ffiffiffiffi
N
p
, where N is
the number of non-hydrogen atoms [36], was applied to
the resulting GoldScores in order to reduce the bias of
docking programs towards higher molecular weight
compounds. For screening WDI and the MDB, in a first
step, ligands comprising a secondary or tertiary amine
moiety were selected (compounds comprising primary
amines were excluded due their unfavourable physico-
chemical properties) and a molecular weight cut-off of
600Da was applied resulting in 13,524 compounds. For
docking this larger number of compounds, the default
parameters for a ‘‘library screening’’ genetic algorithm
were applied.
The ‘‘receiver operating characteristic’’ (ROC) curves
were calculated to assess the accuracy of the used virtual
screening procedure (for details of the method see [37]).
ROC curves are obtained by plotting the sensitivity versus
the specificity of a virtual screening experiment. Sensitivity
is the percentage of truly active compound being selected
from the virtual screening workflow and is calculated by
dividing the number of true positives by the sum of true
positives and false negatives. Specificity, on the other hand
is the percentage of truly inactive compounds being cor-
rectly identified by the virtual screening experiment. It is
calculated by dividing the number of true negative results
by the sum of true negatives and false positives. Thus, in
ROC curves, the activity signal (i.e. % actives) is plotted
versus the detected noise (% inactives) at all possible
detection thresholds.
Generation of a focused library
For generating a focused library, the strategy described by
Verdonk et al. was followed [38]. Thus, in a first step the
distances D(i, j) between all pairs of 138 active hH3R
antagonists with a binding affinity of Ki < 10 nM was
calculated using formula (1), which takes into account the
1D properties (i) number of hydrogen-bond donors (ND),
(ii) number of hydrogen-bond acceptors (NA) and (iii)
number of nonpolar atoms (NNP).
Fig. 3 Cluster analysis of the 418 hH3R ligand data set. The
structural diversity of the studied hH3R ligand data set was analyzed
using MACCS keys and graph-3-point pharmacophore fingerprint as
similarity metrices. Using a Tanimoto coefficient of 0.8 198
individual clusters were obtained using MACCS keys (Top), whereas
the graph-3-point pharmacophore fingerprint yielded 275 clusters
(Bottom)
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Dði;jÞ ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ðNDðiÞNDðjÞÞ2þðNAðiÞ
q
NAðjÞÞ2þðNNPðiÞNNPðjÞÞ2
ð1Þ
Then the average distance Dmin was calculated as an
average of the individual distances D(i, j) over all active
compounds, which resulted in Dmin = 0.55 for the set of
138 inverse hH3R agonists. A focused library was then
generated by chosing ligands from the WDI, which lay
within the distance Dmin to at least one of the 138 highly
active hH3R compounds and—as a further con-
straint—contained a secondary or tertiary amine moiety or
an imidazole group. From the 3298 unitary WDI com-
pounds, which fulfilled these requirements, 473 structures
were randomly chosen for the subsequent validation
experiment.
Pharmacophore based screening
Pharmacophore-based screening was carried out using the
program Catalyst (Accelrys Inc.: San Diego, CA, 2002).
Conformational models were generated for a database of
418 validated hH3R antagonists and for all compounds of
the WDI and MDB by using the default routine of the
program. An energy cut-off of 20 kcalmol–1 from each
energetic minimum structure was set in order to avoid
highly energetic structures. Three pharmacophore models
were then defined based on the template molecules
FUB836, FUB833 and FUB209 in their supposedly bio-
active conformation. In more detail, the generation of the
pharmacophore model based on FUB836 shall be de-
scribed. In order to obtain the allegedly bioactive confor-
mation of FUB836, first a conformational analysis was
carried out in which each torsion angle was rotated in 15
increments. In the energetic global minimum conformation
of the propyloxy linker of FUB836, the protonated piper-
idyl-nitrogen was pointing towards the aromatic ether atom
(C1–N–C2–C3: -159/68/-59; C2 and C3 form part of the
propyloxy linker), thereby impeding that the piperidyl-
nitrogen could interact with D3.32, when placing this
conformation into the hH3R binding site. Furthermore, in
its global minimum conformation, the piperidinopropyl-
oxy-fragment of FUB836 could not be overlaid with more
rigid hH3R antagonists such as 1S,2S-GT2331, when
common interaction sites were assumed for both com-
pounds. For these reasons, an extended conformation was
assumed for the propyloxy-linker (C1–N–C2–C3: -75/-
174/-179), which deviated only 2.4 kJ/mol from the glo-
bal minimum structure in solution. For the two torsion
angles in the spacious aromatic system in the side chain of
FUB836, favourable torsion angles were calculated to be
within the range [–30–30] for the bond between the
phenyl ring and the secondary amine, while four energetic
minima were observed for the bond between the secondary
amine group and the quinoline system at –150, –30, 30, and
150, which were separated by low energetic barriers.
These data were in good agreement with the CCD-structure
VOTFIT (amodiaquine hydroxide dihydrochloride: 28 and
165, respectively).
Pharmacophoric features were then directly defined
upon this alleged bioactive conformation of FUB836. In a
first step, three spheres (see Fig. 4) were defined whereby
the red sphere represents a volume in which positively
charged moieties and imidazole groups of test compounds
have to be accommodated in order to fulfil this pharma-
cophoric feature; the orange sphere represents linker
groups observed in hH3R compounds (ethers, thioethers,
aliphatic un/saturated hydrocarbon chains, cyclopropyl
moieties or aromatic ring systems and hydrophobic groups
as internally defined by Catalyst); and the cyan sphere
represents p-electron rich systems such as aromatic ring
systems (predefined in Catalyst), carbamate, ester, urea,
and thiourea groups and additionally t-butyl moieties. In a
next step, the van-der-Waals volume of FUB836 was in-
cluded as a further constraint. For defining this shape
query, default parameters of Catalyst were used, except for
the value of similarity tolerance, which was adjusted to a
minimum value of 0.45 instead of 0.5 in order to further
increase the number of hH3R antagonists retrieved by this
model. Finally, also forbidden volumes (black spheres)
were defined in order to account for the fact that some
ligands extending into these areas were inactive although
resembling other active compounds. An additional
Fig. 4 Top: Pharmacophoric features defined upon the alleged
bioactive conformation of FUB836 (see text for interpretation).
Bottom: The complete pharmacophore model based on FUB836
additionally including a shape query (blue spheres) and forbidden
volumes (black spheres)
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forbidden volume was defined in proximity to the space
occupied by the positive head-group of hH3R antagonists in
order to avoid larger substituents at this site, which would -
if the pharmacophore model was seen in its context with
the binding site - produce a clash with D3.32 (see Fig. 4).
No pharmacophoric features were defined upon the 4-
aminoquinoline moiety as a high degree of chemical
diversity was observed in active hH3R ligands within this
region. Any restriction regarding chemical features was
thus avoided in the first instance.
For a more stringent screening, a leave-one-out (LOO)
filter was defined on the pharmacophoric features of
FUB836 as depicted in Fig. 5. The FUB836-LOO model
consisted of a combination of five individual pharmaco-
phore models each lacking one pharmacophoric feature
found in FUB836 at a time, with the exception of the
positive ionisable group and the spacer moiety which were
required in all models.
[3H]Na-methylhistamine binding experiments
Competition binding experiments were carried out with
Sf9 cell membranes co-expressing the hH3R, Gao and
Gb1c2 complex. Briefly, membranes were thawed and
sedimented by a 15-min centrifugation at 4 C and
15,000g to remove residual endogenous guanine nucleo-
tides as far as possible and then resuspended in binding
buffer (12.5 mM MgCl2, 1 mM EDTA, and 75 mM Tris/
HCl, pH 7.4). For ligand-competition, membranes (15–
40 lg of protein per tube, depending on the expression
level), 3 nM [3H]NAMH (PerkinElmer Life and Analyti-
cal Sciences, Boston, MA) and test compounds (May-
bridge, Trevillet, UK) at various concentrations were
used. The total volume of the binding reaction was
250 lL. Incubations were performed for 60 min at 25 C
and shaking at 250 rpm. Bound [3H]NAMH was sepa-
rated from free [3H]NAMH by filtration through 0.3%
polyethyleneimine-pretreated GF/C filters using a 48-well
brandel harvester (model M-48R, Brandel, Gaithersburg,
MD, USA), followed by three washes with 2 mL of
binding buffer (4 C). Filter-bound radioactivity was
determined by liquid scintillation counting using Rotis-
zint eco plus cocktail (Carl Roth GmbH + Co. KG,
Karlsruhe, Germany). The experimental conditions chosen
ensured that not more than 10% of the total amount of
[3H]NAMH added to binding tubes was bound to filters.
All analyses of experimental data were performed with
the Prism 4 program (GraphPad Software, San Diego,
CA). Ki values were calculated using the Cheng and
Prusoff equation [39] and a KD of 1,081 nM for
[3H]NAMH
Results
Generation of a homology model of the hH3R
A model of the human histamine H3 receptor missing the
stretch A240-Q346 was generated based on the backbone
coordinates of the crystal structure 1HZX of bovine rho-
dopsin [29]. Favourable side chain conformations were
added using the program SCWRL3.0 [30]. At two sites,
where small residues observed in the structure of bovine
rhodopsin were mutated to sterically more demanding
residues, steric clashes persisted involving
• residues Y3.33 and Y4.57, and
• residues Y2.61, W3.28, W7.40 and W7.43
In order to find reasonable placements for these residues,
two strategies were followed:
For residues Y3.33 and Y4.57, molecular dynamics
(MD) simulations of uncomplexed hH3R models
were carried out in a CCl4/water membrane mimic,
using alternative start conformations for residue
Y4.57. Based on a better overall structural preserva-
tion of the model and a more reasonable hydrogen-
bond pattern evolving between residues T3.37, Y4.57
and E5.46, the placement of Y4.57 into the binding
site was favoured. Such a placement is also in
accordance with the observation that for residue 4.57
an involvement in ligand binding or receptor activa-
tion has been reported for other GPCRs [40–42].
Fig. 5 Features in FUB836
used for the definition of a
leave-one-out pharmacophore
model. While the positive
ionisable moiety/imidazole
group and the spacer moiety
were required in all models, of
all other features each was
allowed to be missed in a
combinatorial way resulting in a
LOO filter embracing five
individual filters
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For the clash involving Y2.61, W3.28, W7.40, and W7.43
too many placements and corresponding start conforma-
tions for MD-simulations would have resulted when fol-
lowing this strategy. Thus, in order to find in an objective
way a reasonable conformation for this part of the binding
site, a docking procedure of antagonist FUB836 (see
Fig. 1) was carried out. Several rotamers were considered
for each residue, for which no definite placement could be
obtained by applying the SCWRL algorithm and which
was likely participating in the binding site. The approxi-
mate position of antagonists in the hH3R binding pocket
was thereby known from mutational studies, which showed
that D3.32 and E5.46 were the major sites of interaction
[22]. During docking FUB836 into all alternative binding
sites, a distance constraint between the piperidyl-nitrogen
of FUB836 and D3.32 was applied. The resulting com-
plexes were then ranked according to the obtained Gold-
Score and the potential energy of the FUB836
conformation within this complex. The binding site
geometry, for which FUB836 obtained the highest docking
score, was considered to be the most likely geometry and
thus further used in subsequent MD simulations. Most
strikingly, W7.43 was predicted to point into the cleft be-
tween helices 1 and 7.
One internal water molecule was included in the
receptor model, which was located in proximity to D2.50
and linked helices 2, 3 and 7 at a comparable position as
water molecule 1b in the structure of bovine rhodopsin
[26].
The final model was submitted to pKa -shift calculations
using the program UHBD [32], which suggested that res-
idue D2.50 was – in analogy to D2.50 in bovine rhodop-
sin—in its protonated state [25].
Generation of a FUB836-hH3R complex
By applying the ‘‘inverse’’ docking of FUB836 into the
hH3R binding site, not only a decision on the placement of
residues Y2.61, W3.28, W7.40 and W7.43 could be taken,
but also a FUB836/hH3R complex was generated.
Characteristics of this complex were:
• an ionic interactions between the piperidyl-nitrogen and
D3.32
• a contact of the exocyclic nitrogen of the 4-amino-
quinoline moiety with E5.46
• the sterically demanding quinoline system of FUB836
occupied the gap between helices 3, 4 and 5
• a hydrogen bond interaction of the endocyclic nitrogen
of the quinoline system with Y5.34
• accommodation of the propyloxy-linker in an extended
conformation in a cleft formed between helices 3, 6 and
7 in proximity to the voluminous leucine residue 7.42.
• cation-p-interactions between the protonated piperidyl-
moiety interacting with D3.32 and residues W3.28,
F7.39 and W7.40
• T-shaped interactions between the aromatic ring linked
to the propyloxy moiety in FUB836 with Y6.51 and
• a parallel-displaced interaction between the aromatic
ring linked to the propyloxy moiety in FUB836 with
Y5.29 from the second extracellular loop
In order to assess if a pKa -shift occurred in proximity to
E5.46, the complex VUF5300/hH3R, in which VUF5300
was interacting with its piperidyl-moiety with D3.32 and in
which the imidazole moiety was located in proximity to
E5.46, was submitted to calculations with the UHBD
program. For the imidazole moiety a significant pKa -shift
from 6.5 to 8.6 was predicted in proximity to E5.46,
indicating that the interaction will be of electrostatic nat-
ure.
When superimposing VUF5300 onto FUB836, the
imidazole moiety of VUF5300 (pKa (imidazole) ~ 6.5,
Ki = 8.05 nM) [43] could be superimposed onto the 4-
aminoquinoline group of FUB836 (expected pKa -value
based upon the similarity to the compound amodia-
quine = 7.53 [44], Ki = 10.04 nM [45]). As an ionic
interaction was predicted between the less basic imidazole
moiety of VUF5300 and E5.46, the same was assumed for
the interaction between the more basic 4-aminoquinoline
moiety of FUB836 with E5.46.
MD-simulations of hH3R models
MD-simulations of an uncomplexed and ligand-complexed
hH3R model were carried out in a DPPC/water environ-
ment. During all simulations conserved interhelical
hydrogen bond contacts were included as distance con-
straints. During the simulation of an uncomplexed hH3R
model, residue W7.43, which had been predicted to point
into the cleft between helices 1 and 7 by the approach of
inverse docking, switched back into a conformation
pointing into the binding pocket. As such a placement is
not compatible with subsequent ligand docking, the simu-
lation was not further prolonged.
During the simulation of the FUB836/hH3R complex,
the placement of W7.43 in the cleft between helices 1 and 7
was preserved and prompted helix 7 to adopt an idealised
helical conformation in proximity to W7.43. Further
overall structural adaptations consisted in a slight outward
shift of helix 4 and the adoption of an idealised helical
conformation of transmembrane segment 1. In proximity to
the binding site no significant changes from the start
geometry were observed after 1ns of MD simulation.
Figure 6 shows the course of root mean square deviation
(RMSD) from the start structure during the MD simulation.
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Validation of the hH3R binding pocket by screening
against a random and focused library
After carrying out an MD-simulation of the FUB836/
hH3R complex, the ligand was removed, and the binding
pocket model was validated for its capability to discrim-
inate between a database comprising 418 active hH3R
antagonists with a range of pKi from 5.29 to 10.04 and a
database comprising either 473 randomly chosen com-
pounds from the WDI (screening against a random li-
brary) or 473 compounds chosen from the WDI based on
their 1D properties, which resembled the 1D properties of
active hH3R antagonists (screening against a focused li-
brary). All ligands, hH3R antagonists and WDI com-
pounds, were docked using the program GOLD and
ranked according to their GoldScore. In case of the
screening procedure against the random library, the
resulting scores were multiplied by the correction term
1=
ffiffiffiffi
N
p
, where N represents the number of non-hydrogen
atoms, before the complexes were ranked [36]. Exemplary
ligand placements obtained during this docking procedure
for an imidazole- and piperidine-containing inverse hH3R
agonist are shown in Fig. 7 for FUB181, and Fig. 8 for
UCL2190, respectively.
When screening was carried out against the random li-
brary, 11.4% WDI ligands scored among the 80% top
ranked hH3R antagonists reflecting a good discrimination
between validated actives and randomly chosen com-
pounds [37]. (Fig. 9, top) When screening was carried out
against the focused library, 23% WDI ligands ranked
among the top 80% scored hH3R antagonists, indicating
that the discrimination of hH3R ligands from WDI com-
pounds with similar 1D physicochemical property was
significantly more difficult (Fig. 9, bottom).
Receptor-based virtual screening using the hH3R
binding site
After the ability of the hH3R binding site to discriminate
between actives and non-actives had been verified, the
hH3R binding site was used for virtual screening of WDI
and MDB. For this purpose, ligands comprising a second-
ary or tertiary amine moiety were selected in a first step
and a molecular weight cut-off of 600Da was applied
resulting in 13,524 compounds. The compounds were
docked using the program GOLD and ranked according to
their GoldScores. Figure 10 shows a histogram comparing
the GoldScores obtained for docking WDI and MDB
compounds to the scores obtained when docking the 418
active hH3R antagonists using the same parameters. As can
be seen from Fig. 10, the mean docking score for the hH3R
actives lay in the cluster of [40, 50] and was thus signifi-
cantly shifted by a value of 20 to higher docking scores,
when compared to the mean value of the distribution of
Fig. 6 Course of RMSD during the simulation of a FUB836/hH3R
complex within the backbone of the transmembrane region. The
simulation protocol included a stepwise reduction of tether forces in
100 ps time scales from 1000 to 500 to 200 to 100 kJmol–1nm–2
(equilibration) before the tethers on the backbone were completely
removed (unconstrained simulation)
Fig. 7 FUB181 [10] in the hH3R binding site. Amino acids varying
between the hH3R and hH4R are shown in red
Fig. 8 UCL2190 [10] in the hH3R binding site. The carbonyl moiety
is located in hydrogen bonding distance to Y4.57, which is in turn
interacting with T3.37 (not shown) and E5.46. Amino acids varying
between the hH3R and hH4R are shown in red
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WDI and MDB compounds ([20, 30]), thereby indicating
that by docking into the hH3R binding site, significant
higher scores were in average obtained for validated hH3R
ligands. At the arbitrary chosen GoldScore cut-off of 40, at
which 66.5% of the validated hH3R antagonists would have
been retrieved, 87% of the WDI and MDB compounds
were filtered out, resulting in 1720 structures, which were
further analysed by visual inspection.
Pharmacophore-based virtual screening
Three pharmacophore models were defined based on the
template molecules FUB836, FUB833 and FUB209 in their
supposedly bioactive conformation. The pharmacophore
models were then used to screen MDB and WDI com-
pounds, for which conformational models had been gen-
erated. For validation purposes, again the database of 418
active hH3R antagonists was simultaneously processed in
order to assess the quality of the pharmacophore models in
terms of retrieving known active hH3R ligands. Applica-
tion of the pharmacophore model based on FUB836 shown
in Fig. 4 resulted in the retrieval of 316/428 ligands from
the hH3R database comprising 418 active hH3R antago-
nists. In order to further increase these percentages, addi-
tional pharmacophore models based upon compounds
FUB833 (Ki = 0.33nM [45]) and FUB209 (Ki = 69nM
[46]). By combining these three models, 369 of 398 (93%)
hH3R ligands with a pKi > 7 could be obtained, while 2668
compounds (2.5% of the entire databases) were retrieved as
hits when screening WDI and MDB. Within this subset of
2668 WDI and MDB hits, the more stringent leave-one-out
(LOO) filter based on FUB836 (see Fig. 5) was applied,
reducing the number of hits to 320.
In order to assess whether all of these 320 compounds
selected were also compatible with the hH3R binding site,
the compounds selected via the pharmacophore search
were additionally docked using GOLD. After ranking and
clustering the candidates into a histogram similar to that
shown in Fig. 10, the distribution of candidate compounds
and validated hH3R antagonists interestingly showed the
same maximum GoldScores indicating that the pre-
screening with Catalyst was successful in selecting com-
pounds that later resulted in a high docking score. By vi-
sual inspection we manually selected seven structurally
diverse top-ranked compounds from the Maybridge Data-
base fullfilling the pharmacophore requirements for
experimental testing (Fig. 11).
Experimental testing of the identified hits
The seven compounds depicted in Fig. 11 were purchased
from Maybridge and experimentally tested for binding to
the hH3R in a competition binding experiment as described
Fig. 9 Top: ROC curve obtained when carrying out GOLD docking
of hH3R actives against a non-focused library of 473 randomly
selected compounds from the WDI. Bottom: ROC curve obtained
when carrying our docking of 418 hH3R actives against a focused
library of 473 ligands. The corrected GoldScores were used as scoring
values
Fig. 10 Comparison of GoldScores obtained when docking WDI/
MDB compounds (grey columns) and hH3R compounds (black
columns) into the hH3R binding site. The distribution of hH3R
compounds is scaled by a factor of 10 in order to facilitate inspection
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in the Materials and Methods section. Results are shown in
Table 2. All seven compounds are active in the range be-
tween 0.079 and 6.3 lM. Two compounds, BTB-08079
and RJC-03033, are active in the nanomolar range. In order
to determine the structural similarity between the seven
retrieved Maybridge compounds and the 418 hH3R ligands
we calculated similarity indices on the basis of MACCS
keys and graph-3-point pharmacophore fingerprints in
MOE. In Table 3 the Tanimoto coefficients of the closest
neighbour in the 428 ligand dataset are listed. Using the
graph-3-point pharmacophore fingerprint the similarity
cutoffs are all below 0.60 indicating the low structural
similarity between the seven hits and the original hH3R
ligand structures. Using the MACCS key, we found several
piperidine derivatives in the original dataset as analogs of
RJC-03033. Interestingly, for the most potent hit BTB-
08079 (79 nM), the lowest similarity with the original
hH3R ligand structures was observed. The dimethylamin-
ofuran fragment, which is already known from the potent
histamine H2 receptor antagonist Ranitidine, has not been
reported so far as structural element of potent H3R
antagonists.
In order to analyze the binding orientation of the seven
Maybridge compounds, we docked them again in the hH3R
binding pocket using GOLD and standard default docking
settings (highest docking accuracy). No constraints were
used for this redocking. The obtained GoldScores are
shown in Table 2. As known from many docking studies,
only a moderate correlation (r2 = 0.65) between the dock-
ing scores and the Ki values was observed for the seven
compounds. However, the most potent inhibitor BTB-
08079 yielded the highest GoldScore value. The interaction
between BTB-08079 and hH3R is shown exemplarily in
Fig. 12. The dimethylaminofuran group interacts with the
residues of the aromatic cage nearby D3.32 (Y2.61, F7.39,
and W7.40). In addition the dimethylamino group makes a
hydrogen bond to D3.32. The general orientation and
conformation of BTB-08079 is similar to the ones observed
for the other investigated hH3R antagonists, e.g. UCL2190
(Fig. 8).
Fig. 11 Hits obtained by
screening the MDB with a
pharmacophore model based
upon FUB836 and subsequently
docking the compounds into the
hH3R model
Table 2 Binding properties of compounds shown in Fig. 9 at hH3R
Compound Ki (nM) GoldScore
HTS-07217 2459 (1.510–4.004) 72.89
PD-00043 1024 (599–1749) 79.21
RJC-03033 383 (249–589) 81.10
BTB-12683 3655 (2266–5896) 65.97
CD-04850 6258 (3775–10370) 60.13
CD-06177 2958 (1940–4510) 82.21
BTB-08079 79 (47–131) 87.89
The ligands were tested as described under Materials and Methods.
Data shown are the means of two experiments performed in duplicate.
Numbers in parentheses represent the 95% confidence intervals. In
addition, the GoldScore of the top-ranked docking solution is
included
Table 3 Structural similarity between the seven hits and the original
418 hH3R ligand data set
Compound Graph-3-point pharmacophore MACCS keys
HTS-07217 0.45 0.65
PD-00043 0.55 0.73
RJC-03033 0.59 0.83
BTB-12683 0.51 0.73
CD-04850 0.47 0.60
CD-06177 0.56 0.63
BTB-08079 0.45 0.57
Tanimoto coefficients between the seven hit structures and the most
similar analogs were calculated on the basis of MACCS keys and
graph-3-point pharmacophore fingerprints
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Discussion and conclusions
In the present work, two well established tools for in silico
screening, namely molecular docking into a rhodopsin-
based homology model and a pharmacophore based search,
were carried out for the hH3R. In contrast to the hH3R
models published so far, the model of our work was relaxed
by molecular dynamics simulations in an explicit DPPC/
water environment, which allowed carrying out the simu-
lation without tether forces on the model backbone, thereby
permitting adjustments of helix geometries and topology to
take place. In order to avoid model deterioration, which is
frequently observed during completely unconstrained MD
simulation, [47] conserved interhelical hydrogen bond
contacts, which have been previously analysed in simula-
tions of a model of bovine rhodopsin [35], were preserved
via the incorporation of distance constraints during the
simulations.
Generation of a homology model of the hH3R and a
FUB836/hH3R complex
The basis for the prior approach was the generation of a
suitable homology model of the hH3R. The main difficulty
during the model generation was the generation of a ligand-
compatible binding site geometry, which was complicated
due to the relatively low number of mutation data and the
fact that at several sites small residues in the rhodopsin
reference structure had been mutated to more voluminous
amino acids in the hH3R sequence. Thus, after the initial
model generation, the binding site was blocked by amino
acid side chains and did not allow the automated docking
of inverse hH3R agonists. In order to still allow an objec-
tive generation of ligand-receptor complexes, ligand
information was included in the placement of amino acids
in an ‘‘inverse docking’’ approach, which resulted in a
binding site geometry capable of accommodating steri-
cally demanding inverse hH3R agonists. Different to a
‘‘normal’’ docking approach, where a binding pocket
conformation is used as a filter in screening structure
databases for compatible ligands, here, a ligand was used
for retrieving the most suitable binding site. FUB836 is a
high affinity ligand with a pKi value of 10.04 [46].
Consequently, the binding conformation of FUB836
should be near to the energetic minimum structure and a
good fit between the ligand and the binding site can be
expected, which should be reflected in a large docking
score. Based on this assumption, FUB836 was flexibly
docked into alternative binding site geometries, which
varied in the placement of amino acid side chains, for
which clashes have been observed after adding side
chains using the program SCWRL.
Although a distance constraint between D3.32 and the
piperidyl-nitrogen of FUB836 was included during this
docking procedure, this constraint merely served to ensure
that FUB836 was placed inside the binding pocket and
not on the surface of the receptor. The orientation of
FUB836 within the binding pocket, i.e. the piperidyl-
nitrogen interacted with D3.32, while the aminoquinoline-
system interacted with E5.46 was not biased by the
inclusion of such a constraint, as the inverse orientation
(i.e. piperidyl-nitrogen interacting with E5.46 and ami-
noquinoline-system interacting with D3.32) was sterically
not possible. The binding site geometry of the FUB836/
hH3R complex, which obtained the highest GoldScore and
which simultaneously accommodated FUB836 in an
energetically favourable conformation (especially in re-
spect to the conformation of the aromatic system in the
side chain of FUB836) was chosen for deciding on a
placement of conflicting amino acid side chains and as a
start conformation for MD-simulation of the FUB836/
hH3R complex.
The incorporation of ligand information into the
generation of the binding site has been recently discussed
also by Evers et al. for the NK1 receptor and was shown
to significantly improve the quality of the obtained
binding site [11]. Similar to the approach described here,
Evers and co-workers generated 100 preliminary homol-
ogy models and used a docking approach to choose a
suitable binding site geometry. The approach herein de-
scribed differs in that a flexible docking of the antagonist
was carried out and that the ranking of the obtained
complexes was based solely on the docking scores rather
than the establishment of required contacts known from
mutational studies. Although computationally more
demanding, this strategy was given preference as no de-
tailed mutational data were available to a priori exclude
or favour any receptor-ligand complex.
Fig. 12 Docked BTB-08079 in the hH3R binding site. The key amino
acid D3.32 is shown in orange and hydrogen bonds between ligand
and receptor are colored magenta. The van-der-Waals volume of the
ligand is displayed
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MD-simulations of hH3R models
In order to relax the energetically still not favourable
models, MD simulations of an uncomplexed hH3R model
and a FUB836/hH3R complex were carried out in a DPPC/
water membran mimic. As an alternative to completely
unconstrained MD simulations, which were shown not to
be suitable for homology model refinement [47], a number
of constraints was included between conserved residues,
which ensured that important contacts within the helix
bundle were preserved during the simulation. At the same
time, structural adaptations of the hH3R model such as a
slight outward shift of helix 4 and the adoption of an
idealised helical conformation of transmembrane segment
1 of the hH3R model were permitted.
Although MD simulations of uncomplexed models
would allow for a more efficient sampling of the binding
site conformation, residue W7.43 showed the tendency to
adopt a rotamer, which was not compatible with the
available ligand data. A possible explanation could be the
interdependence of backbone coordinates and amino acid
side chain placements [30]. Adoption of the backbone
geometry of the reference structure bovine rhodopsin
would thus prompt all amino acid side chains to adopt a
rotamer consistent with these backbone conformations.
K7.43 in bovine rhodopsin is involved in the Schiff-base
linkage and thus points into the binding site. Therefore,
also W7.43 in the hH3R model would be triggered to adopt
a conformation pointing into the binding site independent
on the start-conformation imposed. The difficulty of find-
ing a suitable conformation for helix 7 in GPCR homology
models has been discussed also by Konvicka [48]. Al-
though this work focused mainly on the kink in proximity
to P7.50, Monte Carlo analysis suggested an idealized
helical conformation in proximity of residue 7.43 of the
5HT2a receptor. An analogous conformation was obtained
from the simulation of a complexed hH3R model, where
the explicit consideration of a ligand impeded W7.43 from
switching back into the binding pocket.
On the other hand, the difficulties in finding a consistent
placement for W7.43 could however reflect more than just
shortcomings of a model built on a relatively distant ref-
erence structure with an altered backbone conformation.
When analysing the SAR of hH3R agonists and antagonists,
it became apparent that the binding site geometry in
proximity to D3.32 significantly varied dependent on
which compound was binding. While for agonists the
binding site in proximity to D3.32 was shown to be steri-
cally quite demanding, the same site appeared to easily
accept the more voluminous groups of antagonists [7].
Given the importance of the comparable residue K7.43 in
bovine rhodopsin, one could speculate that also W7.43 in
the hH3R could be involved in receptor activation. In such
a model, antagonists could trigger W7.43 to adopt an
alternative conformation thereby increasing the free vol-
ume around D3.32. If such a mechanism held true, again
the simulation of complexed models would be more goal-
oriented than the simulation of uncomplexed models. An-
other residue showing a similar ‘‘unstable’’ behaviour was
F5.47, which adopted a rotamer pointing into the binding
pocket during the simulation of uncomplexed hH3R mod-
els. For the F5.47A variant a significant drop in potency
was observed suggesting that this residue was involved in
upholding the receptor structure or in receptor activation
[22]. In simulations of antagonist/hH3R complexes the
conformational switch of F5.47 towards the inside of the
binding pocket was inhibited due to the presence of the
ligand. If one assumes a role of F5.47 in activation, the
transition from partial agonism to inverse agonism caused
by slight structural changes, as for example observed in the
series FUB373, FUB335, FUB407 and FUB397 [49] could
be correlated to the conformational changes of F5.47.
Antagonists FUB335 and FUB397 would thus block the
conformational switch of F5.47 due to the structurally more
demanding imidazole side chain.
For the goal of obtaining ligand-compatible binding site
geometries, simulations of antagonist-hH3R complexes
were thus given preference, although here the sampling
efficiency was significantly reduced due to the presence of
the ligand. The time of MD-simulations was restricted to
1ns in order to avoid that the resulting binding site would
be over fitted to the ligand which had been used in the
simulation. The course of RMSD during the simulation of
FUB836/ hH3R is depicted in Fig. 6. Although the RMSD
is only an imprecise measure for the quality of a simula-
tion, it allows to assess if an equilibration of a model has
occurred, which is indicated by a plateau of the RMSD
curve as observed within the transmembrane region in
Fig. 6. Main interactions between FUB836 and the hH3R
binding site are listed in the Result section. Another residue
in the hH3R, yet not interacting with FUB836, was
methionine 6.55, which stabilised the second aromatic ring
in biphenylic systems, such as A-331440 (results not
shown) [50].
Validation of the hH3R binding pocket by screening
against a random and focused library
The resulting binding pocket was then validated with
respect to its ability to accommodate hH3R antagonists
not used during the MD simulation and to discriminate
between validated actives and other randomly chosen
compounds. For this purpose, inverse hH3R agonists and
473 compounds either chosen randomly from the WDI or
via the average distance Dmin (see Methods and Material
section) were docked using the program GOLD. During
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this docking procedure a distance constraint was set be-
tween the polar headgroup of hH3R antagonists and
D3.32 thereby forcing all antagonists into an orientation,
where the polar headgroup is located in proximity to
D3.32.
Although in most studies so far published [16, 18, 27]
the imidazole-moiety of antagonists was assumed to
interact with E5.46, an inverse placement was assumed in
this work for antagonists containing no further basic moi-
eties in their side-chain, resulting in a placement where the
imidazole moiety interacted with D3.32. In our opinion,
this hypothesis is supported by the binding affinities mea-
sured for the antagonists ciproxifan, thioperamide, clo-
benpropit and NNC-0038–1035 described by Jacobsen
et al. [23]. Thus, when assuming that all imidazole moie-
ties of this set of antagonists would interact with E5.46, all
five imidazole-containing compounds should be negatively
affected by the mutation E5.46Q. Yet, for ciproxifan an
increase in affinity was observed and the affinity of thio-
peramide changed only slightly. The dramatic loss in
affinity observed for clobenpropit and NNC-0038-1035
was explained by Jacobsen et al. by a potentially less
favourable interaction of the side chain moieties of these
compounds with E5.46. As it had been outlined in this
study that several antagonists could interact with D3.32 and
E5.46, the imidazole moieties were thus implicitly sug-
gested to interact with D3.32 rather than E5.46. Although it
is also possible, that depending on the specific structure of
an antagonist, different orientations in the binding pocket
could be adopted, the explanation given by Jacobsen et al.
i.e. that the imidazole moiety of an antagonist might as
well interact with D3.32 appears to be a more sound
interpretation of this data set. Furthermore, accommodation
of sterically demanding ligands such as FUB836 or
FUB833 in an orientation, where the piperidyl-moiety is
interacting with E5.46 is sterically not possible due to the
extended aromatic system in the side chain of these com-
pounds, which can not be accommodated in proximity to
D3.32 without resulting in significant structural distortions
of the model during MD-simulations (results not shown).
It thus appeared likely that although the imidazole
moiety in histamine interacted with E5.46, antagonists
containing no further basic moieties in their side-chain
could contact D3.32. The existence of different imidazole
binding environments was further supported by the obser-
vation that species differences only affected antagonists
while agonists showed almost the same affinity at the rat
and the human receptors. Both residues responsible for
species differences (A3.37T and V3.40A) are located in
proximity to E5.46, which is known to interact with the
imidazole moiety of histamine and other hH3R agonists. If
the imidazole moiety of antagonist interacted with E5.46 in
an analogous way as in hH3R agonists, no species influence
should result for antagonists, as the same structural element
as in agonistic compounds (i.e. the imidazole moiety)
would be located at the same receptor point (i.e. E5.46),
which is however not reflected in available experimental
data. Species differences in the model proposed here could
be explained via a hydrogen-bond cluster involving E5.46,
T3.37 and Y4.57. While Y4.57 was anchored to T3.37 in
the human H3R, the mutation A3.37 would disrupt this
interaction resulting in an increased conformational free-
dom of Y4.57, which could thus more easily interact with
functionalities such as carbonyl-containing moieties pres-
ent in ciproxifan [18] or A-304121 [24], which are most
affected by species differences. Compounds which estab-
lish a salt-bridge interaction with E5.46 should be less
affected by species differences as Y4.57 would not influ-
ence ligand binding.
A second assumption made during ligand docking was
to consider all imidazole moieties in their protonated form.
Although imidazole moieties are only slightly basic in
solution (pKa (imidazole) ~ 6.5), in proximity to an acidic
residue (such as glutamic or aspartic acid) significant pKa -
shifts can result as shown for the imidazole moiety of the
compound VUF5300 in proximity to E5.46. A corre-
sponding pKa -shift occurs in proximity to D3.32, thereby
making a protonation of imidazole moieties very likely.
For validating the hH3R binding site obtained from the
simulation of the FUB836/hH3R complex, additionally, a
screening procedure was carried out against a focused li-
brary, as Verdonk and co-workers showed in a recent study
[38], that virtual screening by protein-ligand docking can
result in an artificial enrichment when screening against an
unfocused library. As a more robust alternative they sug-
gested a validation strategy in which docking scores of
actives were compared to the scores obtained when dock-
ing a focused library comprising structures with one-
dimensional properties, similar to the actives. When com-
paring the results of screening against an unfocused library
(11.4% WDI compounds ranking among the 80% top
ranked hH3R antagonists) to the results obtained when
screening against a focused library (23% WDI compounds
ranking among the 80% top ranked hH3R antagonists), a
significantly better enrichment was obtained when screen-
ing against a non-focused library. This can be explained by
the differences in chemical space spanned by the hH3R
antagonists and randomly chosen WDI compounds. Only
52 of the 470 randomly chosen compounds fulfilled the
criterion required for a compound to be part of the focused
library. Preselected WDI compounds with 1D properties,
which resemble those of active hH3R compounds, have
per se an increased likelihood of representing a hit. Thus,
top ranked structures from screening such a focused library
represented interesting structures with potential affinity at
the hH3R.
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Receptor-based virtual screening using the hH3R
binding site
The validated binding pocket was then applied as a filter in
screening WDI and MDB. For this purpose, the GOLD
genetic algorithm adapted for ‘‘library screening’’ was
applied instead of the algorithm adopted for a ‘‘2-fold
accelerated’’ screening used in the validation experiment.
Although its computational performance regarding speed
was significantly better, application of the ‘‘library
screening’’ settings also resulted in a worse separation
when applied in the validation experiment. In this regard,
the hH3R data set was—due to the high number of rotatable
bonds—especially problematic. Although the application
of the ‘‘2-fold accelerated’’ screening settings would be
recommendable for highly flexible ligands, so far, these
settings were computationally too demanding for a feasible
screening.
In Fig. 10 the GoldScores obtained for docking WDI
and MDB compounds were compared to the scores ob-
tained for docking the hH3R ligand data set. The distribu-
tion of hH3R antagonists was shifted by a value of 20 to
higher GoldScores indicating a satisfactory separation.
With a GoldScore cut-off of 40, 66.5% of the validated
hH3R ligands were retrieved while reducing the number of
WDI and MDB compounds to 1720 structures. Depending
on the cut-off value chosen for visual inspection, a sig-
nificant percentage of hH3R compounds was however
withheld by the applied filter, which could be problematic
as no correlation existed between the docking score and the
ligand affinity so that also some high-affinity compounds
would be missed. Still, application of the docking proce-
dure and a GoldScore cut-off of 40 increased the number of
actives to 13.4% compared to 3.0% in the original database
of 13,524 preselected WDI and MDB compounds mixed
with 418 active hH3R ligands.
Pharmacophore-based virtual screening
Due to their high flexibility and huge structural diversity,
hH3R antagonists also hampered the generation of phar-
macophore models by standard means which normally in-
clude the identification of common features required for
binding from a ligand set. This strategy has however the
disadvantage that the entropic contribution to the free en-
ergy of binding is not sufficiently accounted for. If entropic
binders (hydrophobic molecules comprising few functional
moieties for which a high affinity results merely due to the
fact that the desolvation is so favourable) and enthalpic
binders (relatively polar compounds that fit the shape of the
binding site in terms of steric and physico-chemical prop-
erties, yet have a high desolvation cost) are used for the
generation of a common feature model (an automated
strategy for the derivation of a pharmacophore model
implemented in Catalyst), the presence of entropic binders
will result in an underestimation of functional moieties
present in the enthalpic binders.
Although in terms of ligand-specificity, a good fit be-
tween the ligand and the binding pocket is preferable, the
goal in this work was to define a pharmacophore model,
which was able to retrieve most of the ligands from the
hH3R subset, i.e. including also entropic binders. For this
purpose, relatively loose pharmacophore models as shown
in Fig. 4 were defined in the first instance. The choice of
chemical moieties was thereby based on chemical func-
tionalities observed in validated hH3R antagonists and
inspection of the binding pocket. The linker moiety ab-
stracted by the orange sphere and the adjacent hydropho-
bic/p-electron rich system lay in a cleft between helices 3,
6 and 7 of the hH3R model. In this region, the binding
pocket was rather hydrophobic due to residues Y5.29,
Y6.51, F7.39 and L7.42. In order to explain how polar
groups could also be accommodated in this cleft, one could
assume that potential hydrogen bond donor functions were
present in this region, however involved in intramolecular
hydrogen bond interactions. Thus, in order to establish an
interaction with a polar ligand group, an intramolecular
interaction would have to be broken up, resulting in a
negligible netto-gain of enthalpic binding energy due to the
introduced hydrogen bond acceptor. In case of polar groups
such as carbamate, ester, urea or thiourea moieties which
could be superimposed onto the aromatic/hydrophobic
system described by the cyan sphere in Fig. 4, the presence
of a p-electron system capable of establishing a p–p-
interaction with Y5.29 and T-shape interaction with Y6.51
could represent the commonality. In order to augment the
stringency of the pharmacophore model, the molecules’
shape and forbidden volumes were included into the
pharmacophore model of FUB836 (see Fig. 4, bottom).
Application of the pharmacophore model shown in
Fig. 5 resulted in the retrieval of 316/428 ligands from the
hH3R database comprising 418 active hH3R antagonists. In
order to further increase these percentages, additional
pharmacophore models were defined in a similar way
based upon compounds FUB833 and FUB209. By com-
bining a set of 3 pharmacophore models, 93% of the hH3R
ligand-dataset could be retrieved, while the number of WDI
and MDB compounds was reduced to 2668 (=2.5% of the
original database).
In a second screening, the application of a leave-one-out
filter comprising more pharmacophoric features could then
favour the retrieval of compounds that would better fit the
physicochemical properties of the hH3R binding site,
which should ensure receptor selectivity. Further screening
of the 2668 WDI and MDB compounds with the LOO filter
reduced the number of hits to 320. When screening the
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database of 418 inverse hH3R antagonists, only 25% could
be retrieved by the LOO-filter, however the filter was
capable of filtering out 96% of the inactive (pKi < 6) and 84
% of the moderately active hH3R antagonists (6 < pKi < 7).
In order to ensure that compounds selected by the phar-
macophore based screening could be accommodated into
the hH3R binding site, the 320 hits were docked into the
hH3R binding site and ranked according to their GoldScore.
From the best scored complexes, seven compounds were
chosen for experimental testing. All compounds showed
affinity for the hH3R with binding affinities ranging from
79 nM to 6.3 lM, thereby showing that the pharmacophore
model and hH3R binding site model used for ligand docking
also had some predictive value.
Compared to the receptor-based virtual screening by
docking, application of the pharmacophore-based search
resulted in significantly improved results. While in the
docking approach 66.6% of the hH3R ligands were re-
trieved, though limiting the number of WDI and MDB
compounds to approximately 1720 structures, application
of a pharmacophore-based search allowed retrieval of 93%
of active compounds, while reducing the number of WDI
and MDB structures to 2668 compounds (2.5%). The ideal
strategy for the flexible hH3R ligand data set appeared to be
however a combined approach comprising a pre-screening
of commercial databases with relatively loose pharmaco-
phore models that mainly reflect the available volume in
the binding site (e.g. by considering shape queries of ste-
rically demanding ligands and forbidden volumes derived
from ligand superposition) and some essential requirements
for binding such as the protonated head group. This way,
the number of compounds for the subsequent docking was
already significantly reduced which allowed the application
of algorithm settings with better discriminatory properties.
Binding mode analysis
The redocking of the identified seven hits (using default
docking settings and no docking constraints) showed that
they are interacting in a similar way with the H3 receptor as
observed for the other hH3R ligands under study. The basic
nitrogen atom, which is incorporated in a piperidine,
piperazine, morpholine, pyrrolidine or dimethylamino
group, makes a hydrogen bond to D3.32, whereas the
lipophilic parts are interacting with several aromatic resi-
dues. The amino acids Y2.61, F7.39 and W7.40 form an
aromatic cage nearby the negatively charged glutamate
residue (Fig. 12). The docked antagonists are stabilised by
a hydrogen bond to D3.32, and show in addition p-cation
interactions between their lipophilic and protonated head
groups and the residues of the aromatic cage. The lipo-
philic dichlorophenyl group of BTB-08079 is bound in the
hydrophobic cavity nearby helix 5 (Y3.33, L4.56, A4.60,
L5.39, and A5.42), where also the aromatic systems of
FUB181 or UCL2190 are bound (Figs. 7 and 8). Compa-
rable orientations were derived for the other six com-
pounds. The calculated GoldScores for the seven
compounds provide only a qualitative explanation of their
biological activities, an observation known from a variety
of docking studies [51]. However, the most active com-
pound among the detected hits showed the highest docking
score (Table 3).
The analysis of the structural similarity between the VS
hits and the original dataset showed that the applied VS
strategy was able to identify novel lead structures. Only
one compound (RJC-03033) shows higher structural simi-
larity to one of the 418 original antagonists, as indicated by
a Tanimoto coefficient above 0.8 using the MACCS keys.
Interestingly, the most potent hit BTB-08079 shows no
similarity towards the original hH3R ligand data set (cal-
culated either with the MACCS keys or the graph-3-point
pharmacophore fingerprint). The dimethylaminofuran
fragment, which is already known from the potent hista-
mine H2 receptor antagonist Ranitidine, has not been re-
ported so far as structural element for a potent H3R
antagonist. Therefore, BTB-08079 represents an interesting
lead structure for the further development of novel hH3R
antagonists.
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